# Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis

> **NCT02611830** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 383 (actual)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Vedolizumab 300 mg IV
- **DRUG:** Placebo IV
- **DRUG:** Vedolizumab 108 mg SC
- **DRUG:** Placebo SC

## Key facts

- **NCT ID:** NCT02611830
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-18
- **Primary completion:** 2018-05-30
- **Final completion:** 2018-08-21
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02611830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02611830, "Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02611830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*